| Literature DB >> 27092204 |
Tihomir B Mustakov1, Todor A Popov1, Tanya Z Kralimarkova1, Maria T Staevska1, Vasil D Dimitrov1.
Abstract
BACKGROUND: In an attempt to circumvent low response rates and high cost of classical epidemiological trials, we carried out a real-life survey among practicing physicians consulting patients for nasal symptoms. In this fragment of our work we analyze similarities and differences between children and adults and within the different strata of pediatric age.Entities:
Keywords: Allergic rhinitis; Asthma; Children; Nasal symptoms; Treatment practices
Year: 2016 PMID: 27092204 PMCID: PMC4819277 DOI: 10.1186/s40413-016-0103-6
Source DB: PubMed Journal: World Allergy Organ J ISSN: 1939-4551 Impact factor: 4.084
Age strata and gender differences within the surveyed population
| Age strata | Children <5 years | Children 6–12 years | Adolescents 13–17 years | All aged <18 years | Adults ≥18 years | Altogether |
|---|---|---|---|---|---|---|
| Number | 155 (9.2 %) | 176 (10.4 %) | 175 (10.4 %) | 506 (30.0 %) | 1,179 (70.0 %) | 1,685 (100.0 %) |
| % males (of stratum) | 48.4 % | 61.4 % | 61.1 % | 57.3 % | 42.8 % | 47.2 % |
| Significance for gender differences children/adults |
| |||||
| Medium age (years) | 5 | 9 | 16 | 9 | 39 | 30 |
| Age range (years) | 1–5 | 6–12 | 13–17 | 1–17 | 18–88 | 1–88 |
| Mean age (years) | 4.3 | 9.3 | 15.5 | 9.9 | 41.3 | 31.9 |
Differences and similarities between the pediatric and adult populations
| Diagnosis#, characteristics, comorbidities | Prevalence (%) | Odds ratio | 95 % confidence interval |
| |
|---|---|---|---|---|---|
| Children ( | Adults ( | ||||
| Persistent rhinitis | 55.7 | 63.3 | 0.731 | 0.591 ÷ 0.903 | 0.004 |
| Moderately severe/severe rhinitis | 93.7 | 94.6 | 0.850 | 0.549 ÷ 1.317 | 0.468 |
| Leading congestion | 59.9 | 58.8 | 0.954 | 0.772 ÷ 1.180 | 0.666 |
| Exacerbation during the pollen season | 50.2 | 48.2 | 1.087 | 0.882 ÷ 1.339 | 0.436 |
| Impaired school/work performance | 43.6 | 27.8 | 1.258 | 1.004 ÷ 1.576 | 0.046 |
| Impaired sense of smell | 19.1 | 34.7 | 0.392 | 0.302 ÷ 0.508 | 0.000 |
| Cough | 72.5 | 58.7 | 1.859 | 1.480 ÷ 2.336 | 0.000 |
| Asthma(a) | 25.1 | 19.5 | 1.394 | 1.089 ÷ 1.786 | 0.008 |
| Chronic sinusitis(a) | 19.8 | 22.4 | 1.171 | 0.905 ÷ 1.516 | 0.230 |
| Adenoid hypertrophy(a) | 18.6 | 0.4 | 14.618 | 5.370 ÷ 39.793 | 0.000 |
| Nasal polyp(s)(a) | 0.8 | 10.4 | 0.019 | 0.008 ÷ 0.046 | 0.000 |
aChildren below 6 years were excluded from the analysis as the indicated variables cannot be documented reliably for this age group
#Data are based on doctor made diagnosis
Differences within the school age groups of pediatric patients
| Diagnosis, characteristics, comorbidities | Prevalence (%) | Odds ratio | 95 % confidence interval |
| |
|---|---|---|---|---|---|
| Children 6–12 years ( | Adolescents 13–17 years ( | ||||
| Persistent rhinitis | 60.8 | 50.9 | 1.498 | 0.981 ÷ 2.289 | 0.061 |
| Moderately severe/severe rhinitis | 96.0 | 92.6 | 1.937 | 0.754 ÷ 4.978 | 0.170 |
| Leading congestion | 62.5 | 56.6 | 0.782 | 0.510 ÷ 1.198 | 0. 258 |
| Exacerbation during the pollen season | 50.6 | 57.1 | 0.776 | 0.509 ÷ 1.183 | 0.238 |
| Impaired school/work performance | 42.6 | 43.6 | 0.933 | 0.611 ÷ 1.423 | 0.746 |
| Impaired sense of smell | 16.5 | 21.7 | 0.716 | 0.418 ÷ 1.225 | 0.222 |
| Cough | 73.9 | 58.3 | 2.115 | 1.341 ÷ 3.333 | 0.001 |
| Asthma(#) | 31.2 | 20.6 | 1.759 | 1.081 ÷ 2.862 | 0.023 |
| Chronic sinusitis(#) | 19.9 | 22.3 | 1.155 | 0.691 ÷ 1.931 | 0.582 |
| Adenoid hypertrophy(#) | 15.3 | 2.9 | 0.162 | 0.061 ÷ 0.432 | 0.000 |
| Nasal polyp(s)(#) | 0.0 | 2.3 | - | - | - |
#Data are based on doctor made diagnosis
Treatment differences across the pediatric age strata and between children and adults
| Age strata patients | Children <5 years | Children 6–12 years | Adolescents 13–17 years | All aged <18 years | Adults ≥18 years | Altogether |
|---|---|---|---|---|---|---|
| % on oral H1-blockers | 51.6 % | 54.0 % | 44.6 % | 50.0 % | 50.5 % | 50.3 % |
| Significance |
|
| ||||
| % on nasal steroids | 36.1 % | 55.7 % | 49.7 % | 47.6 % | 61.2 % | 57.1 % |
| Significance |
|
| ||||
| (a)% on decongestants | 0.0 % | 0.0 % | 0.6 % | 0.2 % | 1.5 % | 1.1 % |
| Significance |
|
| ||||
| % immuno-therapy | 8.4 % | 17.0 % | 20.6 % | 15.6 % | 9.8 % | 11.5 % |
| Significance |
|
| ||||
(a)Decongestant were applied mainly orally as part of drug combinations